The Daikyo Crystal Zenith Insert Needle Syringe System - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Daikyo Crystal Zenith Insert Needle Syringe System


The Daikyo Crystal Zenith® Insert Needle Syringe System: A first-in-class, prefillable syringe solution for drug administration

Protect your drug product’s integrity with the industry’s first adhesive- and tungsten-free insert needle syringe system – the Daikyo Crystal Zenith Insert Needle Syringe System. Made from a break-resistant cyclic olefin polymer, the insert needle design minimizes potential contamination and product waste due to manufacturing and performance issues associated with traditional glass and staked-needle syringe systems.

The syringe barrel and piston are silicone-oil-free to help maximize purity and reduce risk. The piston with Daikyo Flurotec® barrier film helps minimize the effect of extractables and leachables. Flurotec barrier film also provides superior functional performance without the addition of silicone oil for lubricity. The syringe system is provided sterile and ready-to-fill in a package designed to be compatible with existing filling technologies.

The break-resistant system offers a variety of benefits that maximize value, enhance delivery and minimize risk, including:

  • Designed to maximize stability, purity and efficacy of your drug product
  • Manufactured to exacting standards in a clean room environment
  • 100% vision inspection
  • Potential to reduce protein aggregation caused by packaging materials
  • Excellent glass-like transparency
  • Suitable for high-viscosity products and those requiring low-temperature storage
  • Designed to be compatible with auto-injectors
  • Custom design and molding capabilities provide the flexibility to develop innovative new systems

 

West Pharmaceutical Services, Inc.
Email: westpharmaceuticalservices@westpharma.com
Website: www.westpharma.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here